Patients receiving tyrosine kinase inhibitors (i.e. FMS-like tyrosine kinase 3 [FLT-3] inhibitors) or B-cell lymphoma 2 (BCL-2) inhibitors for acute leukemia are of particular concern: these potent chemotherapy agents can exhibit substantial DDIs with azoles, typically used either to prevent or treat IA.48 Thus, clinicians face a difficult choice between maintaining both effective chemotherapy and maximal antifungal dosing. This evidence concerns the gene FLT3 and acute leukemia.